Gossamer Bio, Inc.
GOSS
Positions held
Your positionsGOSS isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $60.43M | Enterprise value | $43.41M | Trailing P/E | — | Forward P/E | -0.63 |
| PEG | — | Price / book | -0.64 | Beta | 2.21 | Dividend yield | 0.00% |
| Revenue growth | -19.6% | Earnings growth | — | Gross margin | 100.0% | Operating margin | -2.8% |
| Profit margin | -2.4% | ROE | — | ROA | -62.4% | Debt / equity | — |
| Current ratio | 0.53 | Free cash flow | -$29.76M | Analyst recommendation | buy | Mean target | $82.48 |
| 52w high | $309.60 | 52w low | $9.12 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $9.2M | $17.0M | $13.8M | $13.3M | $11.5M |
| Op margin | -282.2% | -264.6% | -333.6% | -313.2% | -337.4% |
| Net income | $16.9M | -$46.7M | -$47.2M | -$48.2M | -$38.3M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$26.1M | -$44.9M | -$46.0M | -$41.6M | -$38.8M |
- Revenue -46% vs prior quarter ($9.2M vs $17M).
- Operating margin compressed to -282.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $48.5M | $115M | $0.0M | $0.0M | — |
| Op margin | -336.8% | -52.2% | — | — | — |
| Net income | -$170M | -$56.5M | -$180M | -$229M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$163M | -$59.9M | -$174M | -$219M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-01 · Gossamer Bio (GOSS) Stock Draws Fresh Price Target Split Before Seralutinib NDA
2026-09-23 · Gossamer Bio Files New Drug Application for Seralutinib
2026-09-16 · Gossamer Bio Appoints Greg Ciongoli to Board of Directors
2026-09-11 · Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
2026-09-09 · Gossamer Bio Announces 1-for-80 Reverse Stock Split
2026-09-04 · Gossamer Bio to Present at Cantor Global Healthcare Conference
2026-08-27 · Gossamer (GOSS) Announced Up to $250M of Financing, but Only $25M is Expected Upfront. Is the Runway Secure?
2026-08-24 · Gossamer Bio announces $250m in funding to advance seralutinib
2026-08-21 · Sector Update: Healthcare Stocks Advance in Afternoon Trading
2026-08-21 · BC-Most Active Stocks
Price (daily)
Full chart · RSI · MACD · patterns